|
Name |
Alanine, N-[N-[N-(3-phenyl-N-propionyl-L-alanyl)-L-valyl]-L-leucyl]-, methyl ester, L-
|
| Molecular Formula | C27H42N4O6 | |
| IUPAC Name* |
methyl 2-[[4-methyl-2-[[3-methyl-2-[[3-phenyl-2-(propanoylamino)propanoyl]amino]butanoyl]amino]pentanoyl]amino]propanoate
|
|
| SMILES |
CCC(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NC(C)C(=O)OC
|
|
| InChI |
InChI=1S/C27H42N4O6/c1-8-22(32)29-21(15-19-12-10-9-11-13-19)25(34)31-23(17(4)5)26(35)30-20(14-16(2)3)24(33)28-18(6)27(36)37-7/h9-13,16-18,20-21,23H,8,14-15H2,1-7H3,(H,28,33)(H,29,32)(H,30,35)(H,31,34)
|
|
| InChIKey |
BAIRFIBQXUHMRS-UHFFFAOYSA-N
|
|
| Synonyms |
Alanine, N-[N-[N-(3-phenyl-N-propionyl-L-alanyl)-L-valyl]-L-leucyl]-, methyl ester, L-; Methyl 11-benzyl-5-isobutyl-8-isopropyl-2-methyl-4,7,10,13-tetraoxo-3,6,9,12-tetraazapentadecan-1-oate #
|
|
| CAS | NA | |
| PubChem CID | 551812 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 518.6 | ALogp: | 1.8 |
| HBD: | 4 | HBA: | 6 |
| Rotatable Bonds: | 15 | Lipinski's rule of five: | Rejected |
| Polar Surface Area: | 143.0 | Aromatic Rings: | 1 |
| Heavy Atoms: | 37 | QED Weighted: | 0.278 |
| Caco-2 Permeability: | -5.252 | MDCK Permeability: | 0.00005730 |
| Pgp-inhibitor: | 0.997 | Pgp-substrate: | 0.751 |
| Human Intestinal Absorption (HIA): | 0.057 | 20% Bioavailability (F20%): | 0.017 |
| 30% Bioavailability (F30%): | 0.059 |
| Blood-Brain-Barrier Penetration (BBB): | 0.118 | Plasma Protein Binding (PPB): | 50.78% |
| Volume Distribution (VD): | 0.325 | Fu: | 25.47% |
| CYP1A2-inhibitor: | 0.005 | CYP1A2-substrate: | 0.047 |
| CYP2C19-inhibitor: | 0.168 | CYP2C19-substrate: | 0.091 |
| CYP2C9-inhibitor: | 0.244 | CYP2C9-substrate: | 0.055 |
| CYP2D6-inhibitor: | 0.009 | CYP2D6-substrate: | 0.097 |
| CYP3A4-inhibitor: | 0.813 | CYP3A4-substrate: | 0.308 |
| Clearance (CL): | 4.557 | Half-life (T1/2): | 0.735 |
| hERG Blockers: | 0.01 | Human Hepatotoxicity (H-HT): | 0.845 |
| Drug-inuced Liver Injury (DILI): | 0.271 | AMES Toxicity: | 0.012 |
| Rat Oral Acute Toxicity: | 0.298 | Maximum Recommended Daily Dose: | 0.021 |
| Skin Sensitization: | 0.028 | Carcinogencity: | 0.008 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.006 |
| Respiratory Toxicity: | 0.011 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC001904 | ![]() |
0.364 | D00UVA | ![]() |
0.461 | ||
| ENC003576 | ![]() |
0.328 | D0RA5Q | ![]() |
0.386 | ||
| ENC002126 | ![]() |
0.299 | D0O5TQ | ![]() |
0.383 | ||
| ENC000717 | ![]() |
0.296 | D0TP2W | ![]() |
0.365 | ||
| ENC004262 | ![]() |
0.289 | D00VFE | ![]() |
0.360 | ||
| ENC003076 | ![]() |
0.278 | D0SH3I | ![]() |
0.351 | ||
| ENC000214 | ![]() |
0.262 | D0ZU9R | ![]() |
0.333 | ||
| ENC002115 | ![]() |
0.255 | D08VRX | ![]() |
0.333 | ||
| ENC000155 | ![]() |
0.254 | D0G6SE | ![]() |
0.326 | ||
| ENC005690 | ![]() |
0.254 | D0X5SJ | ![]() |
0.313 | ||